HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

Benzinga · 10/17 11:03
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $120 price target.